147 related articles for article (PubMed ID: 29844203)
1. Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.
Kubasch AS; Wehner R; Bazzurri S; Tunger A; Stasik S; Garzarolli M; Meinel J; Baretton G; Meier F; Thiede C; Schmitz M; Platzbecker U
Blood Adv; 2018 Jun; 2(11):1187-1190. PubMed ID: 29844203
[TBL] [Abstract][Full Text] [Related]
2. Rare synchronous co-existence of acute myeloid leukemia and hairy cell leukemia in a same patient.
Shi X; Jiang Q; You H; Liu Y; Chen M; Li T; Peng J; Huang R; Liu J; Zhu Y; Xi X
Ann Hematol; 2020 Dec; 99(12):2969-2971. PubMed ID: 32929582
[No Abstract] [Full Text] [Related]
3. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia.
Daver N; Salhotra A; Brandwein JM; Podoltsev NA; Pollyea DA; Jurcic JG; Assouline S; Yee K; Li M; Pourmohamad T; Samineni D; Sumiyoshi T; Vaze A; Dere RC; Ma C; Cooper J
Am J Hematol; 2021 May; 96(5):E175-E179. PubMed ID: 33617672
[No Abstract] [Full Text] [Related]
4. Distinguishing clonal evolution from so-called secondary acute myelogenous leukemia: Adhering to unifying concepts of the genetic basis of leukemogenesis.
Lichtman MA
Blood Cells Mol Dis; 2015 Jun; 55(1):1-2. PubMed ID: 25976458
[No Abstract] [Full Text] [Related]
5. Potential biomarker for acute myeloid leukaemia therapy.
Gourd E
Lancet Oncol; 2017 Aug; 18(8):e438. PubMed ID: 28669738
[No Abstract] [Full Text] [Related]
6. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory.
Renaud L; Nibourel O; Marceau-Renaut A; Gruson B; Cambier N; Lionne-Huyghe P; Choufi B; Rodriguez C; Frimat C; Plantier I; Stalnikiewicz L; Bemba M; Berthon C; Marolleau JP; Quesnel B; Preudhomme C; Duployez N
Am J Hematol; 2019 Jan; 94(1):E24-E27. PubMed ID: 30358899
[No Abstract] [Full Text] [Related]
7. Nivolumab to control molecular response in chronic myeloid leukemia.
Rousselot P; Renard P; de Buyer A; Finet A; Spentchian M; Saiag P
Leuk Res; 2018 Sep; 72():5-6. PubMed ID: 30056299
[No Abstract] [Full Text] [Related]
8. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
9. [Pathogenesis and genetic landscape of acute myeloid leukemia].
Rajnai H; Király AP
Magy Onkol; 2017 Mar; 61(1):21-28. PubMed ID: 28273185
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia and Langerhans' cell histiocytosis: multiple theories for an unusual presentation.
Ghosn MG; Haddad AC; Nassar MN; Abadjian GA; El Karak FR; Aftimos PG
Leuk Res; 2010 Mar; 34(3):406-8. PubMed ID: 19674788
[No Abstract] [Full Text] [Related]
11. Therapy-related acute myeloid leukemia 6 years after clonal detection of inv(11)(q21q23) and MLL gene rearrangement.
Takei N; Suzukawa K; Mukai HY; Itoh T; Okoshi Y; Yoda Y; Nagasawa T
Int J Hematol; 2006 Apr; 83(3):247-51. PubMed ID: 16720556
[TBL] [Abstract][Full Text] [Related]
12. [Combination strategies in melanoma therapy.].
Spagnolo F
Recenti Prog Med; 2017 Dec; 108(12):503-507. PubMed ID: 29297899
[TBL] [Abstract][Full Text] [Related]
13. Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases.
Lu CM; Murata-Collins JL; Wang E; Siddiqi I; Lawrence H
Am J Hematol; 2006 Dec; 81(12):963-8. PubMed ID: 16917916
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of prognostic factors in AML. Preface.
Rowe JM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):485-8. PubMed ID: 22127310
[No Abstract] [Full Text] [Related]
15. A case of acute promyelocytic leukemia presenting with a nonleukemic granulocytic sarcoma of the ovary, with subsequent development of acute myeloid leukemia associated with t(8;21).
Wang X; Liu H; Wu Z; Xu X; Chen X; Zhai Z; Sun Z
Leuk Res; 2009 Apr; 33(4):580-2. PubMed ID: 18804280
[No Abstract] [Full Text] [Related]
16. Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
Hatoum HA; Mahfouz RA; Otrock ZK; Hudaib AR; Taher AT; Shamseddine AI
Am J Hematol; 2007 Jan; 82(1):69-72. PubMed ID: 16947317
[TBL] [Abstract][Full Text] [Related]
17. Collision of metastatic malignant melanoma and acute myelogenous leukemia in the bone marrow.
Kobayashi N; Shimizu H; Hirato J; Handa H
Int J Hematol; 2018 Mar; 107(3):257-259. PubMed ID: 29043550
[No Abstract] [Full Text] [Related]
18. An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling.
Flach J; Dicker F; Schnittger S; Schindela S; Kohlmann A; Haferlach T; Kern W; Haferlach C
Leukemia; 2011 Apr; 25(4):713-8. PubMed ID: 21233836
[No Abstract] [Full Text] [Related]
19. Blood Assay Predicts Response to Pembrolizumab.
Cancer Discov; 2016 Nov; 6(11):1200. PubMed ID: 27698203
[TBL] [Abstract][Full Text] [Related]
20. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
